Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50.
ENDURONYL FORTE vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle via mechanisms involving interference with calcium ion movement and possibly nitric oxide release. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
1 tablet (hydralazine 50 mg/hydrochlorothiazide 50 mg) orally twice daily, maximum 2 tablets daily.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Hydralazine: 2-8 hours (acetylator phenotype dependent; slow acetylators up to 8h, fast acetylators 1-2h). Hydrochlorothiazide: 6-15 hours (mean 10h).
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Hydralazine: 80% renal (mainly as metabolites, 1-2% unchanged), 10% fecal. Hydrochlorothiazide: >95% renal (unchanged) via organic anion transporters.
Category C
Category A/B
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic